Medicare AdvantageCoverageMedium impact
MA08.180, Axatilimab-csfr (Niktimvo™) for Intravenous Use
Independence Blue Cross·Pharmacy, Oncology·Pharmacy
Effective date
Jul 28, 2025
We identified it
Jun 19, 2026
Summary
This is a new Medicare Advantage policy (MA08.180) establishing coverage criteria and billing guidelines for Axatilimab-csfr (Niktimvo™), an intravenous pharmaceutical agent. The billing team must implement this policy effective immediately to ensure claims for this new drug are processed according to the established medical necessity and prior authorization requirements.
Action Required
By 2025-07-28: Billing team must obtain and review the complete MA08.180 policy text to identify specific HCPCS drug codes, prior authorization requirements, and medical necessity criteria for Axatilimab-csfr (Niktimvo™). Contact the policy source at https://medpolicy.ibx.com/ibc/ma/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=07&FilterField2=MPSiteActivityLogYear&FilterValue2=2025 to access full policy details. Update billing system with any required prior authorization workflow. Train billing and clinical staff on coverage criteria. Implement any claim submission requirements or documentation standards specified in the full policy. Failure to follow established criteria may result in claim denials.